Mechanisms of Breaking Indolence in Squamous Cell Carcinoma
打破鳞状细胞癌惰性的机制
基本信息
- 批准号:9137250
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-10-01 至 2020-09-30
- 项目状态:已结题
- 来源:
- 关键词:AffectApoptosisB-LymphocytesBehaviorBiological ModelsCell DeathCell physiologyCellsCessation of lifeComparative StudyDataDyesEpithelialEquilibriumExperimental ModelsFibroblastsHibernationHumanImmuneIn VitroIndividualIndolentInfiltrationInflammatoryKeratinLungMalignant NeoplasmsMediatingMesenchymalMolecularMorbidity - disease rateMouse StrainsMusMutationNeoplasm MetastasisOral cavityPatientsPlasmaPlayPopulationPrimary NeoplasmPropertyRiskRoleSelf-control as a personality traitSideSignal TransductionSiteSkinSmall Interfering RNASquamous CellSquamous DifferentiationSquamous cell carcinomaStem cellsStressSystemT-LymphocyteTestingTherapeuticTimeTransforming Growth Factor betaTransplantationTumor BankTumor Cell InvasionTumor ExpansionTumor ImmunityTumor InitiatorsTumor-DerivedValidationangiogenesisbasebiomarker identificationcancer cellcandidate markercandidate validationcell growthcell motilitychemokinecytokinedesignin vivoknock-downmacrophagemolecular markermouse modelmutantneoplastic celloutcome forecastpredictive markerpublic health relevanceself-renewaltherapeutic evaluationtumor
项目摘要
DESCRIPTION (provided by applicant):
Human squamous cell carcinomas (SCCs) arising from the skin and oral cavity can present in an indolent form, similar to hibernation, with no obvious tumor expansion or local/systemic invasion. SCC indolence, which restricts net tumor expansion and invasion at the primary site, is severely understudied. Very little is known about why indolent SCCs persist and when they evolve into an aggressive form. Without molecular and cellular markers of SCC indolence, they are either over-treated thus causing morbidity or under-treated thus resulting in increased death. To overcome the lack of matched indolent and evolved SCCs in humans for comparative studies, we created a mouse model system, in which tumors developed from the same primary tumor can enter into and break out of indolence. In this system, we targeted a KrasG12D mutant and Smad4 deletion, the two most frequent genetic alterations in human SCCs, into keratin K15+ stem cells. These mice rapidly develop SCCs. After transplanting these SCCs to the skin of immune compromised or immune competent mice, some grew similarly to parental tumors (non-indolent) while others became indolent. When indolent SCCs were out-of-indolence, they grew and metastasized rapidly. This unique model system provides matched indolent and out-of-indolence SCCs for longitudinal comparisons. Based on our preliminary data, we hypothesize: Breaking SCC indolence is not simply leaving proliferative dormancy or overcoming microenvironmental stress. Intrinsic tumor epithelial properties and microenvironmental influences that control self-renewal and motility of tumor cells are key contributors of breaking SCC indolence. Based on our preliminary data, Aim 1 will assess if the numbers and properties of a subset of tumor initiating cells (TICs) influence indolence. Aim 2 will assess if EMT-mediated TIC expansion and cell migration are sufficient to contribute to breaking indolence. Aim 3 will determine the net effect of tumor-associated macrophages and B lymphocytes on tumor indolence. In all three aims, cellular processes and molecules responsible for breaking SCC indolence in mice will be examined in human SCCs from our tumor bank to determine if these cellular and molecular markers correlate with non- or out-of-indolence behavior in human SCCs, thus predicting poor prognosis. Our unique model system, high throughput approaches and cross- species comparisons will significantly accelerate identification of markers associated with breaking SCC indolence. The proposed functional validation of candidate markers will simultaneously test therapeutic strategies to halt SCC evasion.
描述(由申请人提供):
源自皮肤和口腔的人类鳞状细胞癌(SCC)可以以类似于冬眠的惰性形式存在,没有明显的肿瘤扩张或局部/全身侵袭。鳞状细胞癌的惰性限制了肿瘤在原发部位的净扩张和侵袭,但目前对其的研究还严重不足。关于惰性鳞状细胞癌持续存在的原因以及它们何时演变成攻击性形式,人们知之甚少。如果没有鳞状细胞癌惰性的分子和细胞标记,它们要么被过度治疗,从而导致发病,要么被治疗不足,从而导致死亡增加。为了克服人类缺乏匹配的惰性和进化的鳞状细胞癌进行比较研究的问题,我们创建了一个小鼠模型系统,其中由同一原发肿瘤发展而来的肿瘤可以进入和摆脱惰性。在该系统中,我们将人类鳞状细胞癌中两种最常见的基因改变 KrasG12D 突变体和 Smad4 缺失靶向角蛋白 K15+ 干细胞。这些小鼠迅速形成鳞状细胞癌。将这些鳞状细胞癌移植到免疫受损或免疫能力强的小鼠的皮肤后,一些鳞状细胞癌的生长与亲本肿瘤相似(非惰性),而另一些则变得惰性。当惰性鳞状细胞癌脱离惰性时,它们会迅速生长和转移。这个独特的模型系统提供匹配的惰性和非惰性 SCC 以进行纵向比较。根据我们的初步数据,我们假设:打破鳞状细胞癌惰性不仅仅是离开增殖休眠或克服微环境压力。控制肿瘤细胞自我更新和运动的内在肿瘤上皮特性和微环境影响是打破鳞状细胞癌惰性的关键因素。根据我们的初步数据,目标 1 将评估肿瘤起始细胞 (TIC) 子集的数量和特性是否影响惰性。目标 2 将评估 EMT 介导的 TIC 扩张和细胞迁移是否足以有助于打破惰性。目标 3 将确定肿瘤相关巨噬细胞和 B 淋巴细胞对肿瘤惰性的净效应。在这三个目标中,我们将在我们的肿瘤库中的人类鳞状细胞癌中检查负责打破小鼠鳞状细胞癌惰性的细胞过程和分子,以确定这些细胞和分子标记是否与人类鳞状细胞癌中的非或非惰性行为相关,从而预测不良预后。我们独特的模型系统、高通量方法和跨物种比较将显着加速与打破 SCC 惰性相关的标记物的识别。拟议的候选标记物功能验证将同时测试阻止 SCC 逃避的治疗策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Xiao-Jing Wang其他文献
Xiao-Jing Wang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Xiao-Jing Wang', 18)}}的其他基金
Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.
使用放射和双重 TGF-Beta/PD-L1 治疗复发性 HNSCC。
- 批准号:
10477461 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.
使用放射和双重 TGF-Beta/PD-L1 治疗复发性 HNSCC。
- 批准号:
10704598 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.
使用放射和双重 TGF-Beta/PD-L1 治疗复发性 HNSCC。
- 批准号:
10268846 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Mechanisms and Therapeutic Targets of SCC Metastasis
SCC转移的机制和治疗靶点
- 批准号:
10731726 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Mechanisms and Therapeutic Targets of SCC Metastasis
SCC转移的机制和治疗靶点
- 批准号:
10356069 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Testing Smad7-based biologics for treating chronic wounds
测试基于 Smad7 的生物制剂治疗慢性伤口
- 批准号:
8779367 - 财政年份:2014
- 资助金额:
-- - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Regulation of Autophagy and Apoptosis in B lymphocytes
B 淋巴细胞自噬和凋亡的调节
- 批准号:
234605336 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Research Grants
Regulation of apoptosis in B lymphocytes
B 淋巴细胞凋亡的调节
- 批准号:
155495-1997 - 财政年份:2000
- 资助金额:
-- - 项目类别:
Discovery Grants Program - Individual
Regulation of apoptosis in B lymphocytes
B 淋巴细胞凋亡的调节
- 批准号:
155495-1997 - 财政年份:1999
- 资助金额:
-- - 项目类别:
Discovery Grants Program - Individual